BlackRock Japan’s Travere Therapeutics TVTX Stock Holding History

BlackRock Japan’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$15K	Buy	798 +180	+29%	+$3.68K	﹤0.01%	1173
2016 Q3	$14K	Buy	618 +175	+40%	+$3.33K	﹤0.01%	1171
2016 Q2	$8K	Buy	443 +105	+31%	+$1.7K	﹤0.01%	1298
2016 Q1	$5K	Sell	338 -624	-65%	-$9.47K	﹤0.01%	1361
2015 Q4	$19K	Hold	962	–	–	﹤0.01%	1169
2015 Q3	$19K	Hold	962	–	–	﹤0.01%	1096
2015 Q2	$32K	Buy	+962	New	+$26.3K	﹤0.01%	1137

Other funds holding TVTX

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Japan's TVTX Position: Q4 2016 in Review

BlackRock Japan increased its Travere Therapeutics (TVTX) stake by 29% in Q4 2016, buying an estimated $3.68K and bringing the position to 798 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1173.

BlackRock Japan first reported a position in TVTX in Q2 2015 and has held it in 7 quarters since. The position peaked at $32K in Q2 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

BlackRock Japan held 798 shares of Travere Therapeutics worth $15K as of Q4 2016.
BlackRock Japan bought 180 Travere Therapeutics shares in Q4 2016, an estimated $3.68K.
Travere Therapeutics made up ﹤0.01% of BlackRock Japan's portfolio in Q4 2016, its #1173 holding.
BlackRock Japan first reported a position in Travere Therapeutics in Q2 2015 and has held it in 7 quarters since.
BlackRock Japan's Travere Therapeutics position peaked at $32K in Q2 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on BlackRock Japan's 13F filing for Q4 2016, filed 10 Feb 2017.